Health and wellness company XpresSpa Group announced Friday that it has begun construction of an XpresCheck COVID-19 testing facility within Terminal E, the airport’s international terminal. The facility will be “fully operational by November,” and all passengers arriving and departing post security can get tested, according to the company.
“We are eager to launch XpresCheck at Boston Logan International Airport, which will be our third COVID-19 testing facility this fall,” said Doug Satzman, XpresSpa CEO, in a statement. “We believe that our current presence in JFK and Newark, and upcoming expansion to Logan enables us to play an important role in supporting the return of domestic and international air travel to pre-pandemic levels by making sure both airport employees and travelers feel safe and confident when they come to the airport. As previously indicated, our intention is to continue XpresCheck’s national expansion and we remain in active discussions with additional airports for further development of this concept.”
The company’s modular constructed testing facility will have seven separate testing rooms and the ability to administer more than 400 tests per day. The company said it will offer travelers three different tests: a rapid molecular COVID-19 test for $200, a Polymerase Chain Reaction (PCR) test for $75, or a Blood Antibody Test for $75. Travelers can submit insurance claims for the PCR test and Blood Antibody Test, but not the rapid molecular test and airport and airline employees are eligible for a 20 percent discount, a company spokesperson said.
XpresSpa Group also offers XpresCheck testing locations at JFK International Airport and Newark Liberty International Airport.
Tampa International Airport and several U.S. airlines, including JetBlue, Logan’s largest carrier, recently announced COVID-19 testing programs for customers.
Get Boston.com's browser alerts:
Enable breaking news notifications straight to your internet browser.